Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15

Nicotine consumption during the prodromal phase of schizophrenia – a review of the literature

Authors Gogos A, Skokou M, Ferentinou E, Gourzis P

Received 28 March 2019

Accepted for publication 11 July 2019

Published 16 October 2019 Volume 2019:15 Pages 2943—2958

DOI https://doi.org/10.2147/NDT.S210199

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Roger Pinder


Athanasios Gogos,1,* Maria Skokou,2,* Eleni Ferentinou,1 Philippos Gourzis2

1School of Medicine, University of Patras, Rion, Patras, Greece; 2Department of Psychiatry, University Hospital of Patras, Rion, Patras, Greece

*These authors contributed equally to this work

Correspondence: Philippos Gourzis
Department of Psychiatry, General University Hospital of Patras, School of Medicine, University of Patras, University Campus, Rio 26504, Greece
Tel +30 2610 990559
Fax +30 261 099 4534
Email pgourzis@upatras.gr

Abstract: Recent research has fueled a debate concerning the role of nicotine in the emergence of schizophrenia. The three main hypotheses are: (a) the self-medication effect, (b) the causal relationship hypothesis, or (c) the shared diathesis hypothesis. To explore this role, the study of nicotine consumption during the initial prodromal phase of schizophrenia offers important opportunities. In the present work, 10 relevant studies are reviewed, out of 727 retrieved citations, in order to address questions regarding the prevalence of smoking in the prodromal period, the time of smoking initiation, existing patterns of tobacco use in relation with the escalation of prodromal symptoms into first psychotic episode, and potential differences in symptomatology between smokers and nonsmokers. Even though there was considerable heterogeneity among studies, relevant findings are discussed. Prevalence of nicotine use during the prodromal period was reported to be 16.6–46%. Tobacco use was found to be taken up most often before or during the prodromal period of schizophrenia. Even though a protective role of smoking has been reported by one study, other studies report an increased risk for psychosis, with hazard ratios 2.77 (95% CI: 2.34–3.43) and 2.21 (95% CI: 1.11–4.42) for female and male heavy smokers (11–20 and >20 cigarettes/day), respectively. In a different study, the risk of onset was associated with the progressive use of cannabis and tobacco prior to onset, particularly with rapid escalation to the highest levels of use. Also, nicotine use in ultra high risk (UHR) for developing psychosis subjects is associated with elevated cognitive performance, namely better processing speed, visual learning, and spatial working memory. As a conclusion, it appears that evidence accumulates supporting a possible etiologic role of smoking, in the emergence of schizophrenia along with diverse effects on patients’ symptomatology, already demonstrable at the prodromal phase. Future research employing better-defined criteria should further explore the patterns of use and effects of nicotine during the schizophrenia prodrome.

Keywords: tobacco, smoking, psychosis, ultra high risk, conversion, clinical high risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]